Cargando…
An individual patient data meta-analysis of adjuvant therapy with uracil–tegafur (UFT) in patients with curatively resected rectal cancer
Uracil–Tegafur (UFT), an oral fluorinated pyrimidine chemotherapeutic agent, has been used for adjuvant chemotherapy in curatively resected colorectal cancer patients. Past trials and meta-analyses indicate that it is somewhat effective in extending survival of patients with rectal cancer. The objec...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360162/ https://www.ncbi.nlm.nih.gov/pubmed/17375049 http://dx.doi.org/10.1038/sj.bjc.6603686 |
_version_ | 1782152979637338112 |
---|---|
author | Sakamoto, J Hamada, C Yoshida, S Kodaira, S Yasutomi, M Kato, T Oba, K Nakazato, H Saji, S Ohashi, Y |
author_facet | Sakamoto, J Hamada, C Yoshida, S Kodaira, S Yasutomi, M Kato, T Oba, K Nakazato, H Saji, S Ohashi, Y |
author_sort | Sakamoto, J |
collection | PubMed |
description | Uracil–Tegafur (UFT), an oral fluorinated pyrimidine chemotherapeutic agent, has been used for adjuvant chemotherapy in curatively resected colorectal cancer patients. Past trials and meta-analyses indicate that it is somewhat effective in extending survival of patients with rectal cancer. The objective of this study was to perform a reappraisal of randomised clinical trials conducted in this field. We designed an individual patient-based meta-analysis of relevant clinical trials to examine the benefit of UFT for curatively resected rectal cancer in terms of overall survival (OS), disease-free survival (DFS), and local relapse-free survival (LRFS). We analysed individual patient data of five adjuvant therapy randomised clinical trials for rectal cancer, which met the predetermined inclusion criteria. These five trials had a combined total of 2091 patients, UFT as adjuvant chemotherapy compared to surgery-alone, 5-year follow-up, intention-to-treat-based analytic strategy, and similar endpoints (OS and DFS). In a pooled analysis, UFT had significant advantage over surgery-alone in terms of both OS (hazard ratio, 0.82; 95% confidence interval (CI), 0.70–0.97; P=0.02) and DFS (hazard ratio, 0.73; 95%CI, 0.63–0.84; P<0.0001). This individual patient-based meta-analysis demonstrated that oral UFT significantly improves both OS and DFS in patients with curatively resected rectal cancer. |
format | Text |
id | pubmed-2360162 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23601622009-09-10 An individual patient data meta-analysis of adjuvant therapy with uracil–tegafur (UFT) in patients with curatively resected rectal cancer Sakamoto, J Hamada, C Yoshida, S Kodaira, S Yasutomi, M Kato, T Oba, K Nakazato, H Saji, S Ohashi, Y Br J Cancer Clinical Study Uracil–Tegafur (UFT), an oral fluorinated pyrimidine chemotherapeutic agent, has been used for adjuvant chemotherapy in curatively resected colorectal cancer patients. Past trials and meta-analyses indicate that it is somewhat effective in extending survival of patients with rectal cancer. The objective of this study was to perform a reappraisal of randomised clinical trials conducted in this field. We designed an individual patient-based meta-analysis of relevant clinical trials to examine the benefit of UFT for curatively resected rectal cancer in terms of overall survival (OS), disease-free survival (DFS), and local relapse-free survival (LRFS). We analysed individual patient data of five adjuvant therapy randomised clinical trials for rectal cancer, which met the predetermined inclusion criteria. These five trials had a combined total of 2091 patients, UFT as adjuvant chemotherapy compared to surgery-alone, 5-year follow-up, intention-to-treat-based analytic strategy, and similar endpoints (OS and DFS). In a pooled analysis, UFT had significant advantage over surgery-alone in terms of both OS (hazard ratio, 0.82; 95% confidence interval (CI), 0.70–0.97; P=0.02) and DFS (hazard ratio, 0.73; 95%CI, 0.63–0.84; P<0.0001). This individual patient-based meta-analysis demonstrated that oral UFT significantly improves both OS and DFS in patients with curatively resected rectal cancer. Nature Publishing Group 2007-04-23 2007-03-20 /pmc/articles/PMC2360162/ /pubmed/17375049 http://dx.doi.org/10.1038/sj.bjc.6603686 Text en Copyright © 2007 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Study Sakamoto, J Hamada, C Yoshida, S Kodaira, S Yasutomi, M Kato, T Oba, K Nakazato, H Saji, S Ohashi, Y An individual patient data meta-analysis of adjuvant therapy with uracil–tegafur (UFT) in patients with curatively resected rectal cancer |
title | An individual patient data meta-analysis of adjuvant therapy with uracil–tegafur (UFT) in patients with curatively resected rectal cancer |
title_full | An individual patient data meta-analysis of adjuvant therapy with uracil–tegafur (UFT) in patients with curatively resected rectal cancer |
title_fullStr | An individual patient data meta-analysis of adjuvant therapy with uracil–tegafur (UFT) in patients with curatively resected rectal cancer |
title_full_unstemmed | An individual patient data meta-analysis of adjuvant therapy with uracil–tegafur (UFT) in patients with curatively resected rectal cancer |
title_short | An individual patient data meta-analysis of adjuvant therapy with uracil–tegafur (UFT) in patients with curatively resected rectal cancer |
title_sort | individual patient data meta-analysis of adjuvant therapy with uracil–tegafur (uft) in patients with curatively resected rectal cancer |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360162/ https://www.ncbi.nlm.nih.gov/pubmed/17375049 http://dx.doi.org/10.1038/sj.bjc.6603686 |
work_keys_str_mv | AT sakamotoj anindividualpatientdatametaanalysisofadjuvanttherapywithuraciltegafuruftinpatientswithcurativelyresectedrectalcancer AT hamadac anindividualpatientdatametaanalysisofadjuvanttherapywithuraciltegafuruftinpatientswithcurativelyresectedrectalcancer AT yoshidas anindividualpatientdatametaanalysisofadjuvanttherapywithuraciltegafuruftinpatientswithcurativelyresectedrectalcancer AT kodairas anindividualpatientdatametaanalysisofadjuvanttherapywithuraciltegafuruftinpatientswithcurativelyresectedrectalcancer AT yasutomim anindividualpatientdatametaanalysisofadjuvanttherapywithuraciltegafuruftinpatientswithcurativelyresectedrectalcancer AT katot anindividualpatientdatametaanalysisofadjuvanttherapywithuraciltegafuruftinpatientswithcurativelyresectedrectalcancer AT obak anindividualpatientdatametaanalysisofadjuvanttherapywithuraciltegafuruftinpatientswithcurativelyresectedrectalcancer AT nakazatoh anindividualpatientdatametaanalysisofadjuvanttherapywithuraciltegafuruftinpatientswithcurativelyresectedrectalcancer AT sajis anindividualpatientdatametaanalysisofadjuvanttherapywithuraciltegafuruftinpatientswithcurativelyresectedrectalcancer AT ohashiy anindividualpatientdatametaanalysisofadjuvanttherapywithuraciltegafuruftinpatientswithcurativelyresectedrectalcancer AT sakamotoj individualpatientdatametaanalysisofadjuvanttherapywithuraciltegafuruftinpatientswithcurativelyresectedrectalcancer AT hamadac individualpatientdatametaanalysisofadjuvanttherapywithuraciltegafuruftinpatientswithcurativelyresectedrectalcancer AT yoshidas individualpatientdatametaanalysisofadjuvanttherapywithuraciltegafuruftinpatientswithcurativelyresectedrectalcancer AT kodairas individualpatientdatametaanalysisofadjuvanttherapywithuraciltegafuruftinpatientswithcurativelyresectedrectalcancer AT yasutomim individualpatientdatametaanalysisofadjuvanttherapywithuraciltegafuruftinpatientswithcurativelyresectedrectalcancer AT katot individualpatientdatametaanalysisofadjuvanttherapywithuraciltegafuruftinpatientswithcurativelyresectedrectalcancer AT obak individualpatientdatametaanalysisofadjuvanttherapywithuraciltegafuruftinpatientswithcurativelyresectedrectalcancer AT nakazatoh individualpatientdatametaanalysisofadjuvanttherapywithuraciltegafuruftinpatientswithcurativelyresectedrectalcancer AT sajis individualpatientdatametaanalysisofadjuvanttherapywithuraciltegafuruftinpatientswithcurativelyresectedrectalcancer AT ohashiy individualpatientdatametaanalysisofadjuvanttherapywithuraciltegafuruftinpatientswithcurativelyresectedrectalcancer |